A Phase I, Randomized, Observer Blind Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Zoster Vaccine (Adenovirus Vector) in Healthy Adults aged 50-65 years

A Phase I, Randomized, Observer Blind Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Zoster Vaccine (Adenovirus Vector) in Healthy Adults aged 50-65 years

Background An adjuvanted subunit vaccine targeting the gE protein of varicella zoster virus has proven highly efficacious but can be associated with unwanted local and systemic reactions. Alternative strategies that induce polyfunctional T cells with similar efficacy and less reactoge...